Morpholine

Morpholine

SCHEMBL3203810

C1COCCN1.[O]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049109 0.96 MEN1 (0.92)
Morpholine SCHEMBL922866 0.96
Morpholine SCHEMBL18577399 0.96
Morpholine SCHEMBL986 0.96
SCHEMBL244992 0.96 MEN1 (0.92)
Morpholine SCHEMBL7996463 0.96 MEN1 (0.92)
Morpholine SCHEMBL3233209 0.96 MEN1 (0.92)
Morpholine SCHEMBL18434 0.96
SCHEMBL22491036 0.96 MEN1 (0.92)
Morpholine SCHEMBL28529603 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577254-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors Signal Rx Pharmaceuticals, Inc. 2026-03-17 US disclosed
EP-3947351-B1 SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF UNIV TEXAS (US) 2026-03-11 EP disclosed
US-12491188-B2 Small molecule PARG inhibitors and methods of use thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-12-09 US disclosed
US-12291502-B2 Topoisomerase II-alpha inhibitors and methods of treating cancer using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-05-06 US disclosed
WO-2025024400-A2 SUBSTITUTED TRYPTAMINES AND USES THEREOF 2A BIOSCIENCES, INC. (US) 2025-01-30 WO disclosed
EP-4466366-A2 REAGENTS AND SYSTEMS FOR GENERATING BIOSENSORS The Regents of the University of California (US) 2024-11-27 EP disclosed
WO-2024178425-A1 HYDROXYALKYL AND METHOXYALKYL TRYPTAMINES 2A BIOSCIENCES, INC. (US) 2024-08-29 WO disclosed
US-20240241099-A1 METHOD FOR IDENTIFYING PI3 KINASE-ALPHA INHIBITORS UNIVERSITÄT BASEL (CH) 2024-07-18 US disclosed
US-20240150333-A1 TAF1 INHIBITORS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2024-05-09 US disclosed
US-20240109892-A1 POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME NATIONAL INSTITUTES OF HEALTH 2024-04-04 US disclosed
EP-2744330-A1 SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE) BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIITORS University Of Utah Research Foundation (US) 2014-06-25 EP disclosed
US-20140163017-A1 SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE)BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIBITORS UNIVERSITY OF UTAH (US) 2014-06-12 US disclosed
WO-2013025805-A1 SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE) BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIITORS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-02-21 WO disclosed
US-7666646-B2 Crystal structure of human Pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-02-23 US disclosed
US-20070031956-A1 Crystal structure of human PIM-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design VERTEX PHARMACEUTICALS INCORPORATED 2007-02-08 US disclosed
US-6934639-B1 Methods for designing agents that interact with MMP-13 WYETH (US) 2005-08-23 US disclosed
EP-1274980-A4 SOLUTION AND CRYSTAL STRUCTURES OF MMP-13 ACTIVE SITE AND USES THEREOF WYETH CORP (US) 2005-02-09 EP disclosed
CN-1423748-A Solutions and crystal structures of MMP-13 active site and uses thereof WYETH CORP (US) 2003-06-11 CN disclosed
EP-1274980-A1 SOLUTION AND CRYSTAL STRUCTURES OF MMP-13 ACTIVE SITE AND USES THEREOF Wyeth (US) 2003-01-15 EP disclosed
WO-2001063244-A1 SOLUTION AND CRYSTAL STRUCTURES OF MMP-13 ACTIVE SITE AND USES THEREOF WYETH (US) 2001-08-30 WO disclosed